(UroToday.com) The 2026 ASCO annual meeting featured a radioligand innovation in prostate cancer session and a presentation by Dr. Michael Morris discussing CONVERGE-01 Part 3 assessing Ac-225 rosopatamab tetraxetan (CONV01-α) in 177Lu-PSMA-617 pretreated metastatic castration resistant prostate cancer (mCRPC).